Author: Dev
Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion
Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced approval from the US Food and Drug Administration (FDA) for its allogenic bone grafting material NVDX3 to enter an investigational new drug study (IND). NVDX3 is an allogenic bone grafting material forming a new class of regenerative
Read MoreNovadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative
Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults. Originating from Novadip’s 3M3 platform, NVDX3 is an allogeneic bone grafting material created from human
Read More
Phase Four announces monopropellant multi-mode propulsion systems
Phase Four, a leading provider of next-generation electric propulsion (EP) solutions for satellites, has announced the planned commercialization of their monopropellant multimode capability. Using their Maxwell Block III, Phase Four meets electric propulsion performance for a variety of mission profiles, using either ASCENT or hydrazine chemical propellants. Phase Four anticipates
Read More
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution
Emporos, the industry’s leading Pharmacy Commerce System including Point of Sale (POS), and InterLink AI, creator of scripClip, a state-of-the-art, lighted pharmacy will-call system, are delighted to announce they have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for streamlined prescription will-call, checkout, and
Read More
Resolve Therapeutics announces publication of Lupus clinical trial results
Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, has announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus
Read More
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
Novel solution distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample biomodal, an omics-based life sciences technology and analytics company, has announced it’s delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet
Read More
VUV Analytics Announces Publication of ASTM D8519-23
VUV Analytics, Inc. is proud to announce the publication of ASTM D8519-23, a groundbreaking new method for the Determination of Hydrocarbon Types in Waste Plastic Process Oil using Gas Chromatography with Vacuum Ultraviolet Absorption Spectroscopy (GC-VUV). This method is the first of its kind, designed to accurately characterize WPPO produced
Read MoreNovadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial
Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its
Read MoreVUV Analytics announces $20 million financing
VUV Analytics, Inc. has announced that it has raised $20 million in equity financing—led by existing investors S3 Ventures and New Science Ventures—bringing its total funding to over $36 million. The announcement follows the recent launch of the company’s LUMA product and a record year for revenue with its unit
Read More
ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay
ProterixBio, Inc. has announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is
Read MorePhase Four and Impulse Space to collaborate on multi-mode propulsion
Phase Four the creator of the radio-frequency thruster (RF Thruster) for satellite propulsion, has announced that it has signed a memorandum of understanding with Impulse Space, a Space 2.0 pioneer providing agile, economical last-mile space payload delivery capabilities. The companies seek to explore and collaborate on opportunities to develop and
Read More
Introducing Avari Wireless, a state-of-the-art designer & manufacturer of public safety DAS
Avari Wireless has announced the inception of their newly formed company, focusing largely on mission-critical public safety Distributed Antenna Systems (DAS). Built upon decades of DAS industry experience and with a competent team of seasoned sales, R&D and field service staff, Avari Wireless is well-positioned to meet the needs of
Read More